Edition:
India

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

179.53USD
9:28pm IST
Change (% chg)

$2.93 (+1.66%)
Prev Close
$176.60
Open
$177.39
Day's High
$180.00
Day's Low
$177.39
Volume
75,200
Avg. Vol
496,317
52-wk High
$186.41
52-wk Low
$136.78

Select another date:

Thu, Aug 16 2018

Vertex cystic fibrosis drug gets expanded approval for use in infants

U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc's cystic fibrosis drugs to include patients aged between 12 months and 24 months.

Vertex cystic fibrosis drug gets expanded approval for use in infants

Aug 15 U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc's cystic fibrosis drugs to include patients aged between 12 months and 24 months.

Vertex Pharma profit tops estimates on strong launch of new CF drug

Vertex Pharmaceuticals Inc topped analysts' forecasts for quarterly profit on Thursday, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments.

UPDATE 2-Vertex Pharma profit tops estimates on strong launch of new CF drug

* New CF drug Symdeko Q1 sales $34 mln easily tops expectations

BRIEF-Vertex Initiates Phase 3 Studies Of Vx-445, Tezacaftor And Ivacaftor

* VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS

CORRECTED-Vertex Pharma's quarterly profit falls 15.1 percent

April 26 Vertex Pharmaceuticals Inc's quarterly profit fell 15.1 percent, hurt by higher research and development spending.

BRIEF-Vertex Pharmaceuticals Inc Reports Qtrly EPS Of $0.81

* COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BILLION TO $2.80 BILLION

BRIEF-Vertex Pharma CEO's FY 2017 Total Compensation $17.3 Mln

* VERTEX PHARMACEUTICALS INC SAYS CEO JEFFREY LEIDEN'S FY 2017 TOTAL COMPENSATION WAS $17.3 MILLION VERSUS $17.4 MILLION IN FY 2016 - SEC FILING Source text (https://bit.ly/2JVKbq6) Further company coverage:

BRIEF-Veritas Pharma Enters Into Share Purchase Agreement With 3 Carbon Extractions Inc.

* VERITAS PHARMA ENTERS INTO SHARE PURCHASE AGREEMENT WITH 3 CARBON EXTRACTIONS INC. Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Vertex Pharmaceuticals CEO Leiden's 2017 Compensation Was $17.2 Mln

* VERTEX PHARMACEUTICALS INC - CEO JEFFREY LEIDEN'S 2017 TOTAL COMPENSATION WAS $17.2 MLN VS $17.4 MLN IN 2016 - SEC FILING Source text - https://bit.ly/2uQs5Cx Further company coverage:

Select another date: